BiotechTube
Helio Genomics

Helio Genomics

Los Angeles, United States· Est.
heliogenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Helio Genomics is a private, pre-revenue diagnostics company pioneering a liquid biopsy platform for early cancer detection. Founded in 2015, the company combines genomic analysis of cell-free DNA with proprietary artificial intelligence algorithms to identify cancer-associated methylation patterns from a standard blood sample. Its lead program is focused on liver cancer (HCC), with the goal of addressing a significant unmet need in high-risk populations. The company's success hinges on clinical validation, regulatory approval, and demonstrating that its test can improve patient outcomes and be cost-effective within healthcare systems.

Oncology

Technology Platform

AI-driven liquid biopsy platform analyzing cell-free DNA methylation patterns for early cancer detection.

Funding History

1
Total raised:$10M
Series A$10M

Opportunities

The large and growing global population with liver cirrhosis provides a clear, high-risk market for its lead HCC test.
The adaptable AI-genomics platform offers a pathway to expand into multi-cancer early detection, a massive future market.
Rising incidence of NAFLD/NASH in the US and worldwide expands the addressable patient base for liver cancer screening.

Risk Factors

Must prove clinical utility in large trials to change medical guidelines and secure insurance reimbursement.
Faces intense competition from larger, well-funded companies in the liquid biopsy space.
Regulatory approval for a novel diagnostic is a costly and uncertain process with no guaranteed outcome.

Competitive Landscape

Helio Genomics operates in the highly competitive liquid biopsy for early detection market. It faces direct competition from companies like Grail (Illumina), which has a commercially available multi-cancer test, and Exact Sciences, which is developing early detection tests for multiple cancers. Other players like Freenome and Guardant Health are also advancing similar technologies, creating a crowded field with significant R&D and commercial spending.

More companies in AI / Machine Learning →More companies in United States →